5:29 PM
 | 
Jun 25, 2013
 |  BC Extra  |  Top Story

Cytokinetics, Astellas partner for muscle weakness

Astellas Pharma Inc. (Tokyo:4503) and Cytokinetics Inc. (NASDAQ:CYTK) partnered to develop and commercialize skeletal muscle activators to treat diseases and conditions with muscle weakness in a deal worth up to $490 million. The partners will jointly work to identify and optimize...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >